Stockscreener 앱 받기
1.59
10.67%
-0.19
시간 외 거래:
1.54
-0.05
-3.14%
전일 마감가:
$1.78
열려 있는:
$1.79
하루 거래량:
2.25M
Relative Volume:
6.26
시가총액:
$188.93M
수익:
-
순이익/손실:
$-13.73M
주가수익비율:
-12.23
EPS:
-0.13
순현금흐름:
$-3.92M
1주 성능:
-4.79%
1개월 성능:
-7.56%
6개월 성능:
+2.58%
1년 성능:
+68.95%
1일 변동 폭
$1.30
$1.81
1주일 범위
$1.30
$1.82
52주 변동 폭
$0.6295
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
TLSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.59 | 211.51M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2018-12-17 | 개시 | Laidlaw | Buy |
Tiziana Life Sciences Ltd 주식(TLSA)의 최신 뉴스
Tiziana Life Sciences CEO purchases 163,400 shares in open market - Investing.com India
TLSA CEO Bolsters Stake with New Share Acquisition - GuruFocus
Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab - Quiver Quantitative
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - marketscreener.com
Tiziana CEO boosts stake with open-market share purchase - Proactive financial news
Tiziana Life Sciences withdraws proposed public offering due to market conditions - Investing.com
Tiziana Life Sciences Rescinds Proposed Public Offering - Nasdaq
TLSA Cancels Planned Public Offering Amid Market Conditions - GuruFocus
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering - The Manila Times
Tiziana Life Sciences announces withdrawal of proposed public offering - marketscreener.com
Tiziana Life Sciences withdraws proposed share offering - Proactive financial news
TLSA Begins Enrollment for Phase 2 Alzheimer's Clinical Trial - GuruFocus
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4%Here's Why - MarketBeat
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial - Stock Titan
Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer’s trial next week - Proactive financial news
Is Tiziana Life Sciences Ltd a good long term investmentLow Beta Stocks & Make Confident Moves With Forecasting Models - earlytimes.in
Tiziana Life Sciences Shares Drop After Company Unveils Plan to Spin Out IL-6 Program - MSN
Will Tiziana Life Sciences Ltd stock deliver shareholder valueInsider Buying & Daily Stock Trend Watchlist - Newser
How Tiziana Life Sciences Ltd stock reacts to job market data2025 Dividend Review & Stepwise Trade Execution Plans - Newser
Is Tiziana Life Sciences Ltd stock near bottom after declineJuly 2025 Selloffs & Precise Swing Trade Alerts - Newser
Will Tiziana Life Sciences Ltd stock attract ESG investorsWeekly Stock Recap & Low Risk Entry Point Guides - Newser
Tiziana Life Sciences Ltd (TLSA) is looking forward to a strong quarter - setenews.com
Is KN Agri Resources Limited Stock a Safe Long Term Investment Data Breakdown - earlytimes.in
Small cap wrap: Tiziana Life Sciences, Gunnison Copper, Blockmate Ventures, Century Lithium… - Proactive financial news
Is Tiziana Life Sciences Ltd stock undervalued vs historical averagesTrade Exit Report & Weekly Stock Breakout Alerts - Newser
Tiziana Life Sciences to Set Up a Publicly Listed Immunology-Focused Spinout Company, Centered on the IL-6 Market - marketscreener.com
Tiziana Life Sciences stock falls after announcing IL-6 asset spinout By Investing.com - Investing.com Nigeria
Tiziana Life Sciences stock falls after announcing IL-6 asset spinout - Investing.com Nigeria
Tiziana Life Sciences plans spinout of IL-6 antibody program - Proactive financial news
Tiziana Life Sciences (TLSA) Plans Spinout to Develop Anti-IL-6 Antibody - GuruFocus
Tiziana Life Sciences Plans to Spin Off IL-6 Antibody Asset Into New Publicly Listed Company - marketscreener.com
Tiziana Life Sciences Plans to Spin Out Asset as Separate Company - marketscreener.com
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company - The Manila Times
Tiziana Life Sciences (Nasdaq: TLSA) to spin out IL-6 asset into new listed company - Stock Titan
Tiziana Life Sciences Ltd (TLSA) -5.03% in After-hours: What’s Driving the Move? - Stocks Telegraph
Take Profit: Why Tiziana Life Sciences Ltd stock appeals to dividend seekersQuarterly Profit Summary & AI Based Trade Execution Alerts - moha.gov.vn
Ready to Jump After Recent Trade: Tiziana Life Sciences Ltd (TLSA) - Setenews
Tiziana Life Sciences Ltd (TLSA) -5.3% in After-hours: Amid Routine Trading Conditions - Stocks Telegraph
Small cap wrap: Tiziana Life Sciences, Pinnacle Silver & Gold, Rainbow Rare Earths... - Proactive Investors
Phase 2 Trial of Tiziana Life Sciences' Foralumab Gains MyMatch Program Inclusion - GuruFocus
Tiziana Life Sciences’ Phase 2 foralumab trial joins Healey ALS MyMatch Program - Proactive financial news
Tiziana Life Sciences' Foralumab Phase 2 Trial for ALS Accepted into ALS MyMatch Program at Mass General Brigham - Quiver Quantitative
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program - The Manila Times
TLSA ALS Phase 2 intranasal foralumab trial in ALS MyMatch - Stock Titan
Tiziana (Nasdaq: TLSA) Phase 2 nasal foralumab ALS trial joins Healey ALS MyMatch - Stock Titan
Will Tiziana Life Sciences Ltd stock benefit from sector rotation - newser.com
Will Tiziana Life Sciences Ltd stock reach all time highs in 20252025 Performance Recap & AI Driven Stock Reports - newser.com
Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 4.5% – Here’s Why - Defense World
Will Tiziana Life Sciences Ltd stock outperform Nasdaq indexDollar Strength & Daily Profit Focused Screening - newser.com
Tiziana Life Sciences Ltd (TLSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):